{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:02:48Z","timestamp":1773334968447,"version":"3.50.1"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,26]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>The use of anti-CGRP antibody drugs as migraine preventive drugs is increasing worldwide, but there are still a certain number of cases where antibody drugs are ineffective or cannot be used due to high prices. Conventional prophylactic drugs or traditional Japanese medicine (<jats:italic toggle=\"yes\">kampo<\/jats:italic> medicine) are still often used in such cases. However, to date, only limited evidence supports the efficacy of <jats:italic toggle=\"yes\">kampo<\/jats:italic> medicine for headaches because these treatments have been used primarily empirically and traditionally. However, in recent years studies have begun to be published that describe the efficacy of <jats:italic toggle=\"yes\">kampo<\/jats:italic> medicine for various types of headache. Here, we report the case of a patient who achieved a marked reduction in migraine frequency and severity by prophylactic therapy with the <jats:italic toggle=\"yes\">kampo<\/jats:italic> drug yokukansan (TSUMURA Yokukansan Extract Granules).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns and diagnoses:<\/jats:title>\n            <jats:p>The patient was a 50-year-old woman. She began to experience headaches around high school age and was diagnosed with migraine without aura at 42 years of age.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions and outcomes:<\/jats:title>\n            <jats:p>She started prophylactic therapy with amitriptyline and topiramate and this treatment reduced the frequency of migraines for several years. However, the frequency began to increase again around 47 years, which is when she presented at our hospital. We achieved a temporary reduction in migraine frequency by adjusting the dose of drugs in her prophylactic therapy regimen, but the frequency increased again around age 49. We then tried monotherapy with the <jats:italic toggle=\"yes\">kampo<\/jats:italic> medicine yokukansan, and this markedly reduced migraine frequency and severity over the following year. This therapy has remained effective to date.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>We speculate that, in this case, migraine without aura was improved by prophylactic therapy with yokukansan due to its action on the glutamatergic system or serotonin system through suppression of orexin-A secretion or its anti-inflammatory effects as reported in previous animal studies. Yokukansan could be a usable <jats:italic toggle=\"yes\">kampo<\/jats:italic> medicine for migraine prophylaxis in countries all over the world and should be investigated in a large clinical trial as soon as possible.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000039072","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T14:13:51Z","timestamp":1722003231000},"page":"e39072","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Successful treatment with traditional Japanese medicine (kampo medicine) Yokukansan as a migraine prophylactic drug: A case report"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4491-6064","authenticated-orcid":false,"given":"Hisanao","family":"Akiyama","sequence":"first","affiliation":[{"name":"Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shin-Yurigaoka General Hospital, Kanagawa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Yamano","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250716","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/head.12055","article-title":"Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II).","volume":"53","author":"Blumenfeld","year":"2013","journal-title":"Headache"},{"key":"R3-20250716","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1185\/030079906X112769","article-title":"The efficacy of goshuyuto, a typical Kampo (Japanese herbal medicine) formula, in preventing episodes of headache.","volume":"22","author":"Odaguchi","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R4-20250716","first-page":"30","article-title":"Study of the usefulness of goshuyuto for migraine prevention: open crossover study with lomerizine hydrochloride.","volume":"16","author":"Maruyama","year":"2006","journal-title":"Pain Kampo Med"},{"key":"R5-20250716","first-page":"288","article-title":"The effect of goshuyuto for chronic headache: comparison with Keishininjinto using an envelope method.","volume":"11","author":"Seki","year":"1993","journal-title":"Pharma Med"},{"key":"R6-20250716","first-page":"53","article-title":"The effect of goshuyuto for chronic headache.","volume":"22","author":"Maeda","year":"1998","journal-title":"Sci Kampo Med"},{"key":"R7-20250716","first-page":"36","article-title":"The usefulness of goshuyuto for tension-type headache.","volume":"15","author":"Akamine","year":"2000","journal-title":"J Jpn Assoc Orient Psychosom Med"},{"key":"R8-20250716","first-page":"1299","article-title":"The usefulness of Keishininjinto and Chotosan for chronic headache.","volume":"72","author":"Matsumoto","year":"1995","journal-title":"Jpn J Clin Exp Med"},{"key":"R9-20250716","first-page":"171","article-title":"The effect of Chotosan (TJ-47) for chronic headache.","volume":"2","author":"Sadato","year":"1992","journal-title":"Neurosurg Lett"},{"key":"R10-20250716","first-page":"38","article-title":"Clinical effect of Tsumura Chotosan for chronic tension-type headache.","volume":"17","author":"Nagata","year":"1996","journal-title":"JAMA (Japanese edition)"},{"key":"R11-20250716","first-page":"121","article-title":"The effectiveness of Chotosan for chronic tension-type headache.","volume":"22","author":"Takada","year":"1998","journal-title":"Sci Kampo Med"},{"key":"R12-20250716","first-page":"272","article-title":"Clinical effect of Chotosan for headache.","volume":"18","author":"Fukushima","year":"1994","journal-title":"Sci Kampo Med"},{"key":"R13-20250716","first-page":"445","article-title":"Clinical effect of Tsumura Chotosan for chronic headache in patients with cerebrovascular disease.","volume":"27","author":"Kimura","year":"1989","journal-title":"Geriatr Med"},{"key":"R14-20250716","first-page":"2085","article-title":"Clinical effect of Kakkonto for chronic tension headache caused by stiff shoulder.","volume":"72","author":"Yamamoto","year":"1995","journal-title":"Jpn J Clin Exp Med"},{"key":"R15-20250716","first-page":"182","article-title":"Therapeutic effect of Goreisan for headache accompanying hemodialysis.","volume":"34","author":"Noguchi","year":"2010","journal-title":"Sci Kampo Med"},{"key":"R16-20250716","first-page":"46","article-title":"Oriental medical treatment for headache in maintenance dialysis patients.","volume":"27","author":"Muroga","year":"1999","journal-title":"Orient Med"},{"key":"R17-20250716","first-page":"186","article-title":"Regulatory mechanism of water metabolism by Goreisan via aquaporin.","volume":"35","author":"Isohama","year":"2011","journal-title":"Sci Kampo Med"},{"key":"R18-20250716","doi-asserted-by":"crossref","first-page":"e17000","DOI":"10.1097\/MD.0000000000017000","article-title":"Effectiveness of the traditional Japanese Kampo medicine Yokukansan for chronic migraine: a case report.","volume":"98","author":"Akiyama","year":"2019","journal-title":"Medicine (Baltim)"},{"key":"R19-20250716","first-page":"e18326","article-title":"Medication overuse headache successfully treated by Japanese herbal kampo medicine, yokukansan.","volume":"13","author":"Katsuki","year":"2021","journal-title":"Cureus"},{"key":"R20-20250716","first-page":"149","article-title":"Multiple psychopharmacological effects of the traditional Japanese kampo medicine yokukansan, and the brain regions it affects.","volume":"8","author":"Mizoguchi","year":"2017","journal-title":"Front Pharmacol"},{"key":"R21-20250716","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1017\/S146114570800970X","article-title":"A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia.","volume":"12","author":"Mizukami","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"R22-20250716","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1479-8301.2012.00413.x","article-title":"Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of yokukansan, a traditional Japanese medicine.","volume":"12","author":"Iwasaki","year":"2012","journal-title":"Psychogeriatrics"},{"key":"R23-20250716","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3233\/JAD-160418","article-title":"Yokukansan in the treatment of behavioral and psychological symptoms of dementia: an updated meta-analysis of randomized controlled trials.","volume":"54","author":"Matsunaga","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"R24-20250716","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ncn3.12284","article-title":"Protocol paper: effects of yokukansan on medication-overuse headache.","volume":"7","author":"Mitsufuji","year":"2019","journal-title":"Neurol Clin Neurosci"},{"key":"R25-20250716","doi-asserted-by":"crossref","first-page":"6611","DOI":"10.1523\/JNEUROSCI.17-17-06611.1997","article-title":"Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons.","volume":"17","author":"Sahara","year":"1997","journal-title":"J Neurosci"},{"key":"R26-20250716","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1021\/jm025548q","article-title":"Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl) decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.","volume":"45","author":"Filla","year":"2002","journal-title":"J Med Chem"},{"key":"R27-20250716","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/brain\/awx130","article-title":"Cortical glutamate in migraine.","volume":"140","author":"Zielman","year":"2017","journal-title":"Brain"},{"key":"R28-20250716","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1212\/WNL.40.10.1582","article-title":"Neuroexcitatory plasma amino acids are elevated in migraine.","volume":"40","author":"Ferrari","year":"1990","journal-title":"Neurology"},{"key":"R29-20250716","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1468-2982.1993.1302089.x","article-title":"Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks.","volume":"13","author":"Martinez","year":"1993","journal-title":"Cephalalgia"},{"key":"R30-20250716","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1526-4610.2007.00812.x","article-title":"Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine.","volume":"47","author":"Vieira","year":"2007","journal-title":"Headache"},{"key":"R31-20250716","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1468-2982.2004.00750.x","article-title":"Cerebrospinal fluid glutamate levels in chronic migraine.","volume":"24","author":"Peres","year":"2004","journal-title":"Cephalalgia"},{"key":"R32-20250716","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1177\/0333102413487444","article-title":"Glutamate oxaloacetate transaminase: a new key in the dysregulation of glutamate in migraine patients.","volume":"33","author":"Campos","year":"2013","journal-title":"Cephalalgia"},{"key":"R33-20250716","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s13311-018-0616-5","article-title":"Glutamate and its receptors as therapeutic targets for migraine.","volume":"15","author":"Hoffmann","year":"2018","journal-title":"Neurotherapeutics"},{"key":"R34-20250716","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.neuint.2008.07.009","article-title":"Attenuation of abnormal glutamate release in zinc deficiency by zinc and yokukansan.","volume":"53","author":"Takeda","year":"2008","journal-title":"Neurochem Int"},{"key":"R35-20250716","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejphar.2009.09.046","article-title":"Glycyrrhizin and its metabolite 18 beta-glycyrrhetinic acid in glycyrrhiza, a constituent herb of yokukansan, ameliorate thiamine deficiency-induced dysfunction of glutamate transport in cultured rat cortical astrocytes.","volume":"626","author":"Kawakami","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"R36-20250716","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1179\/147683008X301414","article-title":"Suppressive effect of Yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-deficient rats.","volume":"11","author":"Takeda","year":"2008","journal-title":"Nutr Neurosci"},{"key":"R37-20250716","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jep.2009.11.003","article-title":"Partial agonistic effect of yokukansan on human recombinant serotonin 1A receptors expressed in the membranes of Chinese hamster ovary cells.","volume":"127","author":"Terawaki","year":"2010","journal-title":"J Ethnopharmacol"},{"key":"R38-20250716","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuroscience.2012.01.037","article-title":"Geissoschizine methyl ether, an alkaloid in Uncaria hook, is a potent serotonin1A receptor agonist and candidate for amelioration of aggressiveness and sociality by yokukansan.","volume":"207","author":"Nishi","year":"2012","journal-title":"Neuroscience"},{"key":"R39-20250716","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.pnpbp.2008.05.010","article-title":"Repeated administration of yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex.","volume":"32","author":"Egashira","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R40-20250716","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1254\/jphs.11079SC","article-title":"Yokukansan enhances pentobarbital-induced sleep in socially isolated mice: possible involvement of GABA(A) - benzodiazepine receptor complex.","volume":"116","author":"Egashira","year":"2011","journal-title":"J Pharmacol Sci"},{"key":"R41-20250716","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.imr.2018.02.005","article-title":"Yokukansan (kampo medicinal formula) prevents the development of morphine tolerance by inhibiting the secretion of orexin A.","volume":"7","author":"Katayama","year":"2018","journal-title":"Integr Med Res"},{"key":"R42-20250716","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1742-2094-10-145","article-title":"Yokukansan promotes hippocampal neurogenesis associated with the suppression of activated microglia in Gunn rat.","volume":"10","author":"Furuya","year":"2013","journal-title":"J Neuroinflammation"},{"key":"R43-20250716","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3937\/kampomed.64.78","article-title":"Analgesic and anti-stress effects of yokukansan in rats with adjuvant arthritis.","volume":"64","author":"Honda","year":"2013","journal-title":"Kampo Med"},{"key":"R44-20250716","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.2174\/0929867324666170320114713","article-title":"Serotonin receptor binding characteristics of geissoschizine methyl ether, an indole alkaloid uncaria hook.","volume":"25","author":"Ikarashi","year":"2018","journal-title":"Curr Med Chem"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T23:01:25Z","timestamp":1752706885000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":43,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039072","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]}}}